FindTrial
Sign In

CAD-1883

DRUG3 trials

Sponsors

Cadent Therapeutics, Cadent Therapeutics Inc.

Conditions

ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1Essential TremorSpinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 10Spinocerebellar Ataxia Type 17Spinocerebellar Ataxia Type 2Spinocerebellar Ataxia Type 3Spinocerebellar Ataxia Type 6

Phase 2

A Clinical Study to Evaluate CAD-1883 in Essential Tremor
CompletedNCT03688685
Cadent TherapeuticsEssential Tremor
Start: 2019-01-23End: 2019-09-24Updated: 2021-08-05
Study of CAD-1883 for Spinocerebellar Ataxia
WithdrawnNCT04301284
Cadent TherapeuticsARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1, Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1 +7
Start: 2021-06-30End: 2022-12-31Updated: 2021-04-08

Unknown Phase

An open-label, multiple oral dose study to investigate the plasma and CSF pharmacokinetics of CAD-1883 in healthy volunteers
Active, not recruitingNL-OMON47994
Cadent Therapeutics Inc.movement disorders essential tremor (ET) Spinocerebellar ataxia (SCA)
Start: 2019-10-31Target: 8Updated: 2025-09-15